Redhill Biopharma (RDHL) Competitors $1.31 +0.01 (+0.77%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.36 +0.05 (+3.51%) As of 08/22/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDHL vs. CLDI, ALVR, IBIO, CARM, ERNA, GOVX, MTNB, SNPX, TAOX, and LGVNShould you be buying Redhill Biopharma stock or one of its competitors? The main competitors of Redhill Biopharma include Calidi Biotherapeutics (CLDI), AlloVir (ALVR), iBio (IBIO), Carisma Therapeutics (CARM), Ernexa Therapeutics (ERNA), GeoVax Labs (GOVX), Matinas Biopharma (MTNB), Synaptogenix (SNPX), Synaptogenix (TAOX), and Longeveron (LGVN). These companies are all part of the "pharmaceutical products" industry. Redhill Biopharma vs. Its Competitors Calidi Biotherapeutics AlloVir iBio Carisma Therapeutics Ernexa Therapeutics GeoVax Labs Matinas Biopharma Synaptogenix Synaptogenix Longeveron Redhill Biopharma (NASDAQ:RDHL) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Which has stronger valuation & earnings, RDHL or CLDI? Redhill Biopharma has higher revenue and earnings than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRedhill Biopharma$8.04M0.37-$8.27MN/AN/ACalidi BiotherapeuticsN/AN/A-$29.22MN/AN/A Does the media favor RDHL or CLDI? In the previous week, Calidi Biotherapeutics had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 5 mentions for Calidi Biotherapeutics and 4 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 0.25 beat Calidi Biotherapeutics' score of 0.13 indicating that Redhill Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Redhill Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Calidi Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is RDHL or CLDI more profitable? Company Net Margins Return on Equity Return on Assets Redhill BiopharmaN/A N/A N/A Calidi Biotherapeutics N/A N/A -344.45% Which has more volatility & risk, RDHL or CLDI? Redhill Biopharma has a beta of 4.18, suggesting that its stock price is 318% more volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Do insiders & institutionals hold more shares of RDHL or CLDI? 7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryRedhill Biopharma beats Calidi Biotherapeutics on 6 of the 8 factors compared between the two stocks. Get Redhill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDHL vs. The Competition Export to ExcelMetricRedhill BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.01M$2.53B$5.81B$9.76BDividend YieldN/A1.67%4.39%4.06%P/E RatioN/A22.9031.3626.05Price / Sales0.37516.56387.8788.42Price / CashN/A179.1038.0259.36Price / Book-0.365.939.536.60Net Income-$8.27M$31.83M$3.26B$265.65M7 Day Performance-3.68%1.89%2.14%2.00%1 Month Performance-28.42%1.62%3.22%0.46%1 Year Performance-85.48%9.25%30.18%18.88% Redhill Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDHLRedhill BiopharmaN/A$1.31+0.8%N/A-85.5%$3.01M$8.04M0.00210Positive NewsCLDICalidi Biotherapeutics0.7367 of 5 stars$4.10-22.6%N/A-87.1%$12.41MN/A0.0038News CoverageALVRAlloVirN/A$2.46+8.4%N/A-85.4%$12.41MN/A-0.12110Gap UpHigh Trading VolumeIBIOiBio1.8649 of 5 stars$0.74+0.2%$5.00+573.1%-60.9%$12.27M$375K0.00100News CoverageGap DownCARMCarisma Therapeutics2.9813 of 5 stars$0.28-4.5%$1.93+590.0%-79.1%$12.20M$19.63M-0.1820News CoverageShort Interest ↓ERNAErnexa Therapeutics0.2739 of 5 stars$1.61+1.6%N/A-94.6%$12.16M$580K-0.1910Short Interest ↑GOVXGeoVax Labs1.8383 of 5 stars$0.74-2.6%$8.50+1,048.6%-87.9%$12.09M$3.95M-0.3710Short Interest ↑Gap UpMTNBMatinas Biopharma0.691 of 5 stars$1.71-27.5%N/AN/A$12.01MN/A-0.3530High Trading VolumeSNPXSynaptogenixN/A$8.40-8.6%N/A+110.7%$11.68MN/A-0.834Gap UpTAOXSynaptogenixN/A$8.34-0.7%N/AN/A$11.67MN/A-0.414Earnings ReportGap UpLGVNLongeveron3.4259 of 5 stars$0.81+6.4%$7.25+796.2%-68.9%$11.54M$2.39M-0.1320 Related Companies and Tools Related Companies Calidi Biotherapeutics Competitors AlloVir Competitors iBio Competitors Carisma Therapeutics Competitors Ernexa Therapeutics Competitors GeoVax Labs Competitors Matinas Biopharma Competitors Synaptogenix Competitors Synaptogenix Competitors Longeveron Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RDHL) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access